Bristol Orencia Pharmacovigilance Plan Could Become Industry Standard

Bristol-Myers Squibb's proposed pharmacovigilance program for its rheumatoid arthritis therapy Orencia (abatacept) is indicative of a trend toward enhanced safety monitoring, Arthritis Advisory Committee industry representative Roger Porter (formerly with Wyeth) said Sept. 8